These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
575 related items for PubMed ID: 17201722
1. Use of levetiracetam in hospitalized patients. Falip M, Carreño M, Amaro S, Donaire A, Delgado R, Toledo M, Maestro I. Epilepsia; 2006 Dec; 47(12):2186-8. PubMed ID: 17201722 [Abstract] [Full Text] [Related]
2. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Steinhoff BJ, Somerville ER, Van Paesschen W, Ryvlin P, Schelstraete I. Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453 [Abstract] [Full Text] [Related]
3. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Wu XY, Hong Z, Wu X, Wu LW, Wang XF, Zhou D, Zhao ZX, Lv CZ. Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175 [Abstract] [Full Text] [Related]
4. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA). Stefan H, Wang-Tilz Y, Pauli E, Dennhöfer S, Genow A, Kerling F, Lorber B, Fraunberger B, Halboni P, Koebnick C, Gefeller O, Tilz C. Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615 [Abstract] [Full Text] [Related]
5. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Peltola J, Coetzee C, Jiménez F, Litovchenko T, Ramaratnam S, Zaslavaskiy L, Lu ZS, Sykes DM, Levetiracetam XR N01235 Study Group. Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886 [Abstract] [Full Text] [Related]
6. Levetiracetam as a treatment option in non-convulsive status epilepticus. Rupprecht S, Franke K, Fitzek S, Witte OW, Hagemann G. Epilepsy Res; 2007 Mar; 73(3):238-44. PubMed ID: 17161587 [Abstract] [Full Text] [Related]
7. Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. Xiao Z, Li JM, Wang XF, Xiao F, Xi ZQ, Lv Y, Sun HB. Eur Neurol; 2009 Mar; 61(4):233-9. PubMed ID: 19176965 [Abstract] [Full Text] [Related]
8. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Beran RG, Berkovic SF, Black AB, Danta G, Hiersemenzel R, Schapel GJ, Vajda FJ. Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083 [Abstract] [Full Text] [Related]
12. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Callenbach PM, Arts WF, ten Houten R, Augustijn P, Gunning WB, Peeters EA, Weber AM, Stroink H, Geerts Y, Geerts AT, Brouwer OF. Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011 [Abstract] [Full Text] [Related]
13. Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome. García C, Rubio G. Epilepsy Res; 2009 Aug; 85(2-3):318-20. PubMed ID: 19423296 [Abstract] [Full Text] [Related]